Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective

Bibliographic Data

ID21880090
AuthorsHugo C Turner (0000-0002-8428-3874, University of Oxford, corresponding author), Wilma A Stolk (0000-0001-9509-1328, Erasmus MC), Anthony W Solomon (0000-0001-7101-6649, World Health Organization), Jonathan D King (0000-0002-6051-8501, World Health Organization), Antonio Montresor (0000-0003-3103-8872, World Health Organization), David Molyneux (0000-0001-8537-7947, Liverpool School of Tropical Medicine), David H Molyneux (Liverpool School of Tropical Medicine), Jaspreet Toor (0000-0003-1510-397X, University of Oxford)
Year2021
Volume6
Issue8
Pagese005456
Publication date2021-08-01
Open AccessYes
TypeARTICLE
VenueBMJ Global Health (JOURNAL)
Journal identifiersISSN: 2059-7908 • E-ISSN: 2059-7908
PublisherBMJ (PUBLISHER • GB)
DOI10.1136/bmjgh-2021-005456
PMID34385158
OpenAlexW3189338891
LanguageEN
Citations received2
References cited97

Neglected tropical diseases (NTDs) remain a significant cause of morbidity and mortality in many low-income and middle-income countries. Several NTDs, namely lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases (STH) and trachoma, are predominantly controlled by preventive chemotherapy (or mass drug administration), following recommendations set by the WHO. Over one billion people are now treated for NTDs with this strategy per year. However, further investment and increased domestic healthcare spending are urgently needed to continue these programmes. Consequently, it is vital that the cost-effectiveness of preventive chemotherapy is understood. We analyse the current estimates on the cost per disability-adjusted life year (DALY) of the preventive chemotherapy strategies predominantly used for these diseases and identify key evidence gaps that require further research. Overall, the reported estimates show that preventive chemotherapy is generally cost-effective, supporting WHO recommendations. More specifically, the cost per DALY averted estimates relating to community-wide preventive chemotherapy for lymphatic filariasis and onchocerciasis were particularly favourable when compared with other public health interventions. Cost per DALY averted estimates of school-based preventive chemotherapy for schistosomiasis and STH were also generally favourable but more variable. Notably, the broader socioeconomic benefits are likely not being fully captured by the DALYs averted metric. No estimates of cost per DALY averted relating to community-wide mass antibiotic treatment for trachoma were found, highlighting the need for further research. These findings are important for informing global health policy and support the need for continuing NTD control and elimination efforts

Cost effectiveness · Environmental health · Filariasis · Lymphatic filariasis · Mass drug administration · Neglected tropical diseases · Onchocerciasis · Pathology · Population · Psychological intervention · Public health · Trachoma · Global Maternal and Child Health · Medicine · Parasites and Host Interactions · Parasitic Diseases Research and Treatment · Immunology

  • Economic evaluations of community health worker programs focussed on neglected tropical diseases in low- and middle-income countries (2015–2024)

    Open Access•Linnea Stansert Katzen, Madelyn Miyares et al.•PLOS Global Public Health•2025

  • Current state and future directions of interventions for neglected tropical diseases

    Open Access•John Owusu Gyapong, Mawuli Gohoho et al.•Nature Human Behaviour•2025

  • Methods for the Economic Evaluation of Health Care Programmes

    Bernie J O'Brien, Michael E Drummond et al.•Methods for the economic…•2005

  • Halys and Qalys and Dalys, Oh My

    Marthe R Gold, David Stevenson et al.•Annual Review of Public Health•2002

  • Country-Level Cost-Effectiveness Thresholds

    Open Access•Beth Woods, Paul Revill et al.•Value in Health•2016

  • Common values in assessing health outcomes from disease and injury

    Open Access•Joshua A Salomon, Theo Vos et al.•The Lancet•2012

  • Thresholds for the cost–effectiveness of interventions

    Open Access•Elliot Marseille, Bruce A Larson et al.•Bulletin of the World Health…•2015

  • Worms

    Open Access•Edward Miguel, Michael Kremer•Econometrica•2004

Citations per year2
Citation span2025 - 2025 (1)
Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae